

1 **Trial of labor or elective cesarean delivery for low-lying**  
2 **placenta? A propensity score analysis.**

3 **Alizée FROELIGER<sup>1</sup>, MD, MPH; Hugo MADAR<sup>1</sup>, MD, MPH; Pauline JEANNETEAU<sup>2</sup>, MD,;**  
4 **Vanessa RUIZ<sup>2</sup>, MD, Maela LE LOUS<sup>3</sup>, MD; Franck PERROTIN<sup>4</sup>, MD, PhD; Norbert**  
5 **WINER<sup>5</sup>, MD, PhD; Michel DREYFUS<sup>6</sup>, MD, PhD; Philippe MERVIEL<sup>7</sup>, MD, PhD; Aurélien**  
6 **MATTUIZZI<sup>1</sup>, MD; Eric JAUNIAUX<sup>8</sup>, MD, PhD, FRCOG; Loïc SENTILHES<sup>1</sup>, MD, PhD,**  
7 **FRCOG.**

8 *1 Department of Obstetrics and Gynecology, Bordeaux University Hospital Center, France*

9 *2 Department of Obstetrics and Gynecology, Angers University Hospital Center, Angers,*  
10 *France.*

11 *3 Department of Obstetrics and Gynecology, Rennes University Hospital Center, Rennes,*  
12 *France.*

13 *4 Department of Obstetrics and Gynecology, Tours University Hospital Center, Tours, France.*

14 *5 Department of Obstetrics and Gynecology, Nantes University Hospital Center, Nantes,*  
15 *France.*

16 *6 Department of Obstetrics and Gynecology, Caen University Hospital Center, Caen, France.*

17 *7 Department of Obstetrics and Gynecology, Brest University Hospital Center, Brest, France.*

18 *8 EGA Institute for Women's Health, Faculty of Population Health Sciences, University College*  
19 *London, London, United Kingdom.*

20  
21 **Corresponding author**

22 Pr Loïc Sentilhes

23 Department of Obstetrics and Gynecology

24 Bordeaux University Hospital Center,

25 Place Amélie Raba Léon, 33076 Bordeaux, France.

26 Tel: (33) 5 56 79 55 79 Fax: (33) 5 56 79 59 85 Email: loicsentilhes@hotmail.com

27

28 **Financial Disclosure**

29 Loïc Sentilhes carried out consultancy work and was a lecturer for Ferring Laboratories in the  
30 previous 3 years. The other authors did not report any conflict of interest.

31

32 **Financial support for the research**

33 This research received no specific grant from any funding agency in the public, commercial,  
34 or not-for-profit sectors.

35

36 Presented at the 42st Annual Pregnancy Meeting of the Society for Maternal Fetal Medicine,  
37 January 31 – February 5, 2022, Orlando, Florida.

38

39 **Word count abstract:** 318

40 **Word count main text:** 3,082

41

42 **Short title**

43 Planned mode of delivery in low-lying placenta

44

45 **Acknowledgments**

46 The authors thank Jo Ann Cahn for her help in editing this manuscript.

47

48 **Précis**

49 Trial of labor in women with low-lying placenta around term is not associated with higher risks  
50 of maternal or neonatal complications than elective cesarean delivery.

51 **Abstract**

52 **OBJECTIVE:** To compare outcomes of women with low-lying placenta by their planned  
53 mode of delivery and according to the internal os distance (IOD), while using  
54 propensity score analysis to ensure the study groups' comparability and minimize  
55 indication bias.

56 **METHODS:** Six tertiary maternity hospitals in France participated in this retrospective  
57 multicenter study of births from 2007 through 2012. Women with a low-lying placenta,  
58 defined as an IOD  $\leq$  20mm who gave birth after 35 weeks of gestation were included  
59 and classified in the planned trial of labor or elective cesarean groups. The main  
60 endpoint was severe postpartum hemorrhage, defined as blood loss exceeding 1,000  
61 mL. Secondary outcomes were composite variables of severe maternal and neonatal  
62 morbidity. Using multivariable logistic regression and propensity score methods, we  
63 compared outcomes by planned mode of delivery.

64 **RESULTS:** Among 128,233 births during the study period, 171 (0.13%) women had a  
65 low-lying placenta: 70 (40.9%) in the trial-of-labor group and 101 (59.1%) with elective  
66 cesareans. The vaginal delivery rate in the trial-of-labor group was 50.0% (19/38) in  
67 the 11-20 mm subgroup and 18.5% (5/27) in the 1-10 mm subgroup. Severe  
68 postpartum hemorrhage occurred in 22.9% (16/70, 95% confidence interval [CI] 13.7–  
69 34.4) of the trial-of-labor group and 23.9% (23/101, 95%CI 15.2–32.5) of those with  
70 elective cesareans ( $P=.9$ ); severe maternal and neonatal morbidity rates were likewise  
71 similar (respectively 2.9% versus 2.0%,  $P=.7$ , and 12.9% versus 9.9%,  $P=.5$ ).  
72 Attempted labor was not significantly associated with a higher rate of severe  
73 postpartum hemorrhage after multivariable logistic regression and propensity score-  
74 weighted analysis: respectively aOR 1.42, 95%CI 0.62–3.24,  $P=0.4$ , and aOR 1.34,  
75 95%CI 0.53–3.38,  $P=.5$ .

76 **CONCLUSION:** Our results support a policy of offering trial of labor to women with a  
77 low-lying placenta after 35 weeks and an IOD of 11-20mm. An IOD of 1-10mm reduces  
78 considerably the likelihood of vaginal birth compared to 11-20mm but without  
79 increasing the incidence of severe postpartum hemorrhage or severe maternal  
80 morbidity.

81

82

83 **Key words:** low-lying placenta, placenta previa, trial of labor, cesarean delivery,  
84 maternal morbidity, propensity score, postpartum hemorrhage.

## 85 **Introduction**

86 Low-lying placenta, defined as a distance between the cervical os and the placenta  
87 (internal os distance, IOD)  $\leq 20$  mm is a cause of maternal and neonatal morbidity and  
88 mortality.<sup>1-4</sup> It increases the risk of ante-, intra-, and post-partum hemorrhage, blood  
89 transfusion, hysterectomy, sepsis, and thrombophlebitis.<sup>5</sup> The prevalence low-lying  
90 placenta has increased over the past two decades due to rising numbers of cesarean  
91 deliveries<sup>6-8</sup> and of pregnancies resulting from medically assisted reproduction.<sup>6,9,10</sup>  
92 Their combined prevalence of both placenta previa (defined as the placenta lying  
93 directly over the internal os) and low-lying placenta in the literature varies widely and  
94 is estimated at around 0.5% of pregnancies at term.<sup>3,7</sup>

95 All national guidelines and expert opinions on the management of placenta  
96 previa have recommended delivery by elective cesarean delivery between 36 and 38  
97 weeks of gestation in women with uncomplicated placenta previa.<sup>2-5,11</sup> A broad  
98 consensus also exists to propose trial of labor at term to women with an IOD  $> 20$  mm  
99 in the absence of other contraindications. By contrast, for women with a third-trimester  
100 asymptomatic low-lying placenta,<sup>1</sup> mode of delivery remains controversial. No  
101 guidelines exist in the USA<sup>3,5</sup> to guide this decision. Practices seem likely to be similar  
102 to those in Canada<sup>4</sup> where an elective cesarean is recommended for an IOD  $\leq 10$  mm  
103 due to the high hemorrhage risk, while individualized management is proposed when  
104 the edge is between 11 and 20 mm from the os, in the absence of antenatal  
105 complications. In the UK<sup>2</sup> and France,<sup>11</sup> the mode of delivery in women with a third-  
106 trimester asymptomatic low-lying placenta is based on her clinical background and her  
107 preferences, supplemented by transvaginal ultrasound imaging of the placental  
108 position.

109           Only a few studies have examined perinatal outcomes in women diagnosed with  
110 a low-lying placenta at term.<sup>12-20</sup> None provide data on antenatal symptoms or on the  
111 indication for either planned mode of delivery. Furthermore, most used study protocols  
112 that did not take the intended treatment into account and were thus likely to introduce  
113 a selection bias.<sup>12-17,19,20</sup> A randomized controlled trial might resolve this question, but  
114 difficulties in recruiting and ethical concerns undoubtedly make such a study  
115 impossible.

116           Our study's aim was to evaluate and compare the maternal and neonatal  
117 morbidity of women with a low-lying placenta according to their planned mode of  
118 delivery and stratified by the IOD at the last ultrasound examination before delivery,  
119 while using propensity score analysis to ensure comparability of the study groups and  
120 minimize the indication bias.

121

## 122 **Materials and Methods**

123 Six tertiary maternity hospitals in France participated in this retrospective multicenter  
124 study of births from 2007 through 2012. Each hospital searched their database for all  
125 consecutive case files with one of the following International Classification of Diseases,  
126 10<sup>th</sup> edition (ICD-10) codes: ICD-10 O44 and O43.2. These codes correspond to  
127 placenta previa and low-lying placenta, with or without hemorrhage and to placenta  
128 accreta spectrum (PAS). Each paper file was first reviewed by two independent  
129 investigators (PJ and VR) to identify only low-lying placenta and avoid  
130 misclassification. Women were not eligible for the study if their medical files were  
131 incomplete, contained a classification error, or if the delivery took place outside a  
132 participating center. Then, each medical charts were reviewed to include women who  
133 met the inclusion criteria: women with singleton or multiple pregnancies who were  
134 diagnosed with a low-lying placenta (IOD less than 20 mm at the last transvaginal  
135 ultrasound before delivery) and gave birth at or after 35 weeks of gestation. Exclusion  
136 criteria included placenta previa, antenatal suspicion of PAS, and termination of  
137 pregnancy. The inclusion and diagnostic criteria were the same for all six centers.  
138 In France, in addition to the last mandatory ultrasound performed at 32 weeks of  
139 gestation where the placental location must be mentioned, an additional ultrasound is  
140 recommended in case of placenta previa or low-lying placenta at 36 weeks of gestation  
141 to determine the IOD and therefore the planned mode of delivery.<sup>11</sup>

142 For each center, medical charts were reviewed to collect the following data:  
143 maternal baseline clinical characteristics, course of labor, mode of delivery, postpartum  
144 hemorrhage, and maternal and neonatal outcomes. We also sought to retrieve  
145 variables that might have influenced the choice of the planned mode of delivery. The

146 Research Ethics Committee at Angers University Hospital Center (Ref 2013/50)  
147 approved this study.

148 The main endpoint was severe primary postpartum hemorrhage, defined as  
149 blood loss more than 1,000 mL within 24 hours after delivery,<sup>21,22</sup> measured with a  
150 collector bag in case of vaginal birth and with graduated drapes, suction canister or  
151 weighing in case of cesarean delivery.<sup>11,23-25</sup> This endpoint also includes intrapartum  
152 blood loss which was cumulative.<sup>11,22</sup> Intrapartum hemorrhage was defined by a blood  
153 loss requiring emergency cesarean delivery.<sup>5,11,26</sup> The main secondary endpoint was  
154 severe maternal morbidity, as previously described<sup>24, 27-29</sup> and defined by any one of  
155 the following: use of uterine artery embolization or emergency surgery to control  
156 postpartum hemorrhage, transfusion of more than 5 units of packed red blood cells,  
157 transfer to the intensive care unit (ICU), thromboembolic events, and death. Another  
158 secondary endpoint was severe neonatal morbidity including: 5-minute Apgar score <  
159 7, umbilical artery pH < 7.10, need for resuscitation or intubation with transfer to the  
160 neonatal ICU (NICU), and neonatal death.<sup>30</sup>

161 Exposure was the planned mode of delivery. Each medical chart was specially  
162 reviewed by two independent investigators (PJ and VR) to ensure among other the  
163 accuracy of the planned mode of delivery. Trial of labor was defined as a planned trial  
164 of labor per medical records, regardless of ultimate mode of delivery, i.e. successful  
165 vaginal delivery or an emergency cesarean performed before or during labor for severe  
166 intrapartum bleeding, abnormal fetal heart rate, or failure to progress. An elective  
167 cesarean delivery was defined as a planned cesarean per medical records, performed  
168 before labor regardless of the indication, or during labor for women entering in labor  
169 before the planned date of cesarean delivery recorded in the medical files. Women



170 with a history of 2 or more cesareans CDs had elective cesareans, in accordance with  
171 French guidelines.<sup>31</sup>

172 Analyses were conducted with STATA software (version 15; StataCorp, College  
173 Station, TX). Continuous variables were described by their medians and interquartile  
174 ranges (IQR) and compared between groups by a Kruskal-Wallis test. Categorical  
175 variables were described by proportions and compared by Chi2 or Fisher's exact tests,  
176 as appropriate.

177 To control for confounding factors that might have influenced both the choice of  
178 the planned mode of delivery and the primary endpoint, we began the analysis with  
179 logistic regression models with multiple adjustments to estimate crude and adjusted  
180 odds ratios (aORs) and their 95% confidence intervals (CIs). Variables included in the  
181 multivariable analysis were chosen based on the literature and other hypotheses of  
182 potential confounders. Because practitioners' decisions about planned mode of  
183 delivery are probably guided by characteristics of the woman and her pregnancy rather  
184 than by chance, we performed a second analysis using a propensity score to limit  
185 potential indication bias.<sup>32,33</sup> An inverse probability of treatment weighting based on a  
186 propensity score was used to control for factors that might influence both management  
187 choice and primary outcome. The propensity score was defined as each woman's  
188 probability of attempting labor, based on her individual characteristics, and was  
189 estimated with a multivariable logistic regression model including the following  
190 covariates: maternal age, body mass index before pregnancy, nulliparity, previous  
191 cesarean delivery, recurrent episodes of antepartum hemorrhage, anterior placental  
192 location, and distance between the cervical os and the placenta. We assigned women  
193 planning to try labor a weight of  $1/(\text{propensity score})$  and those who with an elective

194 cesarean a weight of  $1/(1-\text{propensity score})$ . Balance among covariates was checked  
195 by using standardized differences.

196 A sensitivity analysis was performed with multiple imputation of missing data.  
197 The proportion of women with missing data for any covariate included in the main  
198 multivariable model ranged from 1% to 8%. We performed multiple imputation chained  
199 equations according to Rubin's rules for those missing data (10 data sets imputed).<sup>34</sup>  
200 A separate analysis was performed according to IOD, i.e., 1-10 mm and 11-20 mm. A  
201 *P* value  $<.05$  was considered significant.

## 202 **Results**

203 During the study period, the six university hospital centers recorded 128,233 births,  
204 including 1,089 coded ICD-10 O44 and O43.2. Figure 1 presents the case selection  
205 flowchart: 171 cases were available for analysis, including 70 (40.9%) in the trial-of-  
206 labor group and 101 (59.1%) in the elective cesarean group.

207 Table 1 summarizes maternal and pregnancy characteristics according to  
208 planned mode of delivery. Women included in the trial-of-labor group had significantly  
209 lower rates of previous cesarean delivery ( $P=.01$ ) and higher rates of both antepartum  
210 hemorrhage ( $P<.01$ ) and hospitalization for it ( $P<.01$ ). Recurrent bleeding episodes  
211 were less frequent ( $P=.01$ ) in the trial-of-labor group. The median interval (days)  
212 between delivery and the last ultrasound was shorter (4 days, IQR 0–16 versus 10.5,  
213 IQR 3–17,  $P<.01$ ), and the median IOD was longer (13.5 mm, IQR 9–17 versus 9 mm  
214 IQR 0–13,  $P<.01$ ) in the trial-of-labor than in the elective cesarean group.

215 Table 2 presents the maternal and neonatal outcomes by planned mode of  
216 delivery. The rate of severe PPH ( $> 1,000$  mL) was similar in both groups (trial-of-labor  
217 group 22.9%, 95%CI 13.7–34.4 versus 23.0%, 95%CI 15.2–32.5,  $P=0.9$ ). The vaginal  
218 delivery rate in those planning to attempt labor was 38.6% (27/70). Moreover, the  
219 multivariable logistic regression analysis showed that trial of labor was not significantly  
220 (aOR 1.42, 95% CI 0.62–3.24,  $P=0.4$ ) associated with a higher rate of severe  
221 postpartum hemorrhage after adjustment for maternal age, prepregnancy BMI,  
222 nulliparity, previous cesarean delivery, and IOD (Supplemental file A). Results were  
223 similar for the multivariable analysis after multiple imputations (aOR 1.39, 95%CI 0.65–  
224 2.84,  $P=.5$ ) and for the propensity score-weighted model (aOR 1.34, 95%CI 0.53–3.38,  
225  $P=.5$ ) (Figure 2). Differences in women’s characteristics at baseline were well balanced  
226 between the two groups after propensity score weighting, with all standardized

227 differences less than 10%, except for the variable of prepregnancy BMI  $\geq 30$ ; its  
228 standardized difference was 11% after propensity score weighting (Supplemental file  
229 B).

230 The rate of severe maternal morbidity did not differ significantly between the  
231 trial-of-labor and elective cesarean groups (respectively, 2.9% (2/70) versus 2.0%  
232 (2/101),  $P=.7$ ), nor did that of severe neonatal morbidity (12.9% (9/70) versus 9.9%  
233 (10/101),  $P=.5$ ) (Table 2).

234 Table 3 compares the perinatal outcomes according to the IOD. In women who  
235 planned trial of labor, the rate of vaginal delivery was 50.0% (19/38) in the 11-20 mm  
236 subgroup and 18.5% (5/27) in the 1-10 mm subgroup and the rate of emergency  
237 cesarean delivery for bleeding before or during labor was 27.0% (10/37) in the 11-20  
238 mm subgroup and 50.0% (13/26) in the 1-10 mm subgroup. Neither maternal nor  
239 perinatal outcomes differed significantly between them.

240

241 **Comment**

242 Our results indicate that almost 40% of women with a low-lying placenta at or near  
243 term who attempt labor have a successful vaginal birth with no increase in their risk of  
244 maternal or perinatal complications compared to women with elective cesareans. In  
245 particular, trial of labor did not result in a higher severe postpartum hemorrhage rate  
246 after controlling for confounding by indication with a propensity score analysis. An IOD  
247 of 11-20 mm at the last transvaginal ultrasound before delivery increased the chance  
248 of a vaginal birth compared to a measurement of 1-10 mm.

249 Our findings are similar to those of the only study comparing maternal and  
250 neonatal outcomes according to planned mode of delivery in women with a low-lying  
251 placenta.<sup>18</sup> It was much smaller, including only 18 women with low-lying placentas  
252 diagnosed at 36 weeks as well as 6 with an IOD exceeding 20 mm at delivery. The  
253 authors did not control for the selection and indication biases, and the mode of delivery  
254 was determined by the women's preference.

255 Our results about the success of vaginal delivery according to the IOD are also  
256 consistent with those of a systematic review/meta-analysis by Jansen et al. of 10  
257 studies, including 7 retrospective cohort studies intended to evaluate the likelihood of  
258 vaginal delivery in women with a low-lying placenta. Among the 478 such women in  
259 this meta-analysis, vaginal delivery was successful at an IOD of 0-10 mm in 43% and  
260 of 11-20 mm in 85%. The authors further stated that postpartum hemorrhage did not  
261 differ significantly by IOD in any cohorts.<sup>35</sup> Moreover, they underlined that only three  
262 studies<sup>13,14,18</sup> compared blood loss by mode of delivery, with inconsistent results<sup>35</sup>: one  
263 study found no difference,<sup>14</sup> while two others found significantly more intrapartum  
264 hemorrhages and blood transfusions in women with cesarean versus vaginal  
265 births.<sup>13,18</sup>

266 This meta-analysis nonetheless has important limitations. First, most of the  
267 studies included in this review used a methodology that did not take the intended  
268 treatment into account, and Jansen et al. provide no comparison of maternal outcomes  
269 by planned mode of delivery, i.e., cesarean or trial of labor. While they reported that  
270 30-60% of cases chose to deliver by planned cesarean, this could have been due to  
271 unfavorable conditions for attempting labor (short IOD, for example), which might have  
272 resulted in planned cesareans for the less stable patients and thus overestimation of  
273 the success rate of vaginal delivery.<sup>35</sup> Simultaneously, this failure to take the intended  
274 treatment into account is likely to have introduced a selection bias by allocating to the  
275 trial-of-labor group, women who did not have a an elective cesarean because of their  
276 favorable prognosis. Moreover, their inclusion of women with an emergency cesarean  
277 during labor due to intrapartum hemorrhage after attempted labor to the cesarean  
278 group would also introduce bias by worsening the maternal prognosis in the cesarean  
279 group. This may explain why two of the three studies that assessed blood loss by actual  
280 mode of delivery found significantly higher blood loss and transfusion rates in the  
281 cesarean than in the vaginal group.<sup>13,18</sup> Furthermore, among the studies included in  
282 this meta-analysis reporting blood loss by the IOD or the actual rather than planned  
283 mode of delivery, only one provided information about how blood loss was assessed  
284 (with a collector bag),<sup>18</sup> three studies defined postpartum hemorrhage using different  
285 cutoffs for vaginal and cesarean deliveries,<sup>16,19,21</sup> and one did not define postpartum  
286 delivery at all.<sup>20</sup> All of these points limit the robustness of the results reported by Jansen  
287 et al.<sup>35</sup>

288 Our data, obtained by using a propensity score to limit indication bias, support  
289 a policy of trial of labor for women diagnosed with a low-lying placenta presenting  
290 around term with an IOD of 11 -20 mm. Attempting labor is also a possible option for

291 women when this distance is 1-10 mm as the incidence of blood-loss related maternal  
292 outcomes including severe postpartum hemorrhage did not differ between the trial-of-  
293 labor and elective cesarean groups. Avoiding unnecessary cesareans in women with  
294 low-lying placenta is crucial to limiting the occurrence of low-lying placenta, placenta  
295 previa, vasa previa, and placenta accreta spectrum in this population in subsequent  
296 pregnancies. Nevertheless, the shared decision-making should emphasize that the  
297 need for emergency cesarean during labor was considerably higher in women with the  
298 shortest IOD and reached about 80% in this group.

299 Transvaginal ultrasound has become essential in the diagnosis, follow-up, and  
300 management of women with a low-lying placenta. Most studies, including ours, have  
301 focused on the IOD. Small, observational, and retrospective studies have suggested  
302 that women with a low-lying placenta are more likely to need a cesarean delivery when  
303 the placental edge is thicker ( $>10$  mm)<sup>15,36</sup> or contains a sponge-like echo<sup>37</sup> or marginal  
304 "sinus".<sup>18</sup> These additional ultrasound features are poorly defined and not routinely  
305 assessed in current practice. Their use to advise women with a low-lying placenta  
306 about mode of delivery requires further research.

307 The main strengths of our study were (1) the comparison of trial of labor with  
308 elective cesarean delivery, rather than women with vaginal to those with cesarean  
309 delivery, as the latter comparison is obviously biased in favor of the vaginal delivery  
310 group, and (2) use of propensity score analyses to ensure that the study groups were  
311 comparable and to minimize the impact of uncontrolled confounders and especially  
312 indication biases linked to mode of delivery.

313 Second, for our primary analysis, only births at or after 35 weeks' gestation were  
314 included to limit confounding, as no perinatal center had an elective cesarean policy  
315 before this gestational age. Thus, before 35 weeks' gestation, it was likely that trial of

316 labor was allowed only in the most favorable conditions (preterm labor without  
317 bleeding), and elective cesarean delivery performed in the poorest conditions (severe  
318 antenatal bleeding).

319 The primary limitation of our cohort study lies in its retrospective design.  
320 Nonetheless, all the data of the study cases were collected according to a defined  
321 protocol. While eligible cases might have been missed, the combined prevalence of  
322 low-lying and placenta previa observed in our study (0.56%) is consistent with rates  
323 reported in the literature.<sup>3,7</sup>

324 Second, unmeasured confounders may persist despite our use of cautious  
325 statistical approaches — sensitivity, multivariable, and propensity score analyses. A  
326 randomized controlled trial would undeniably be the best study design for comparing  
327 the effects of planned mode of delivery, but its feasibility seems doubtful. Third, the  
328 infrequency of severe maternal morbidity such as second-line therapies to control  
329 postpartum hemorrhage (pelvic arterial embolization or surgical therapies), admission  
330 to intensive care, thromboembolic events, or maternal death limited our statistical  
331 power to detect potentially clinically meaningful differences between planned modes  
332 of delivery. In addition, considering the small difference in postpartum hemorrhage  
333 rates between the trial-of-labor and elective cesarean groups (respectively 22.9%  
334 versus 23.0%), we acknowledge that our study is underpowered to confirm an absence  
335 of difference in maternal adverse outcomes. Nonetheless, a post hoc analysis  
336 determined that with a sample size of 171 patients and 23% of deliveries complicated  
337 by severe postpartum hemorrhage in the unexposed group (elective cesarean group),  
338 the study would have had a power of 80% and an alpha risk of 0.05, able to detect an  
339 OR > 2.5 in the univariate logistic regression. It would also have been able to detect  
340 an OR > 2.5 in univariate logistic regression for the risk of postpartum hemorrhage



341 above 500 mL. Lastly, since our data are quite dated, we cannot exclude that practices  
342 of antenatal imaging and labor management may have evolved.

343

#### 344 **Conclusion**

345 Our results support a policy of offering trial of labor to women with a low-lying placenta  
346 at or after 35 weeks of gestation and a distance of 11–20 mm between the placental  
347 edge and the internal os on ultrasound. While a distance of 1–10 mm does not increase  
348 the incidence of severe postpartum hemorrhage or severe maternal morbidity, it  
349 strongly reduces the likelihood of successful vaginal delivery, compared with 11-20  
350 mm, from 50% to 18.5%.

351 **References**

- 352 1. Reddy UM, Abuhamad AZ, Levine D, Saade GR, Fetal imaging: Executive  
353 Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health  
354 and Human Development, Society for Maternal-Fetal Medicine, American  
355 Institute of Ultrasound in Medicine, American College of Obstetricians and  
356 Gynecologists, American College of Radiology, Society for Pediatric Radiology,  
357 and Society of Radiologists in Ultrasound Fetal Imaging Workshop. *Am J Obstet*  
358 *Gynecol.* 2014;210:387-97. doi: 10.1016/j.ajog.2014.02.028.
- 359 2. Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL et al; Royal  
360 College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta  
361 Accreta: Diagnosis and Management: Green-top Guideline No. 27a. *BJOG.*  
362 2019;126:e1-e48. doi: 10.1111/1471-0528.15306.
- 363 3. Silver RM. Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta  
364 Accreta. *Obstet Gynecol.* 2015;126:654-68. doi:  
365 10.1097/AOG.0000000000001005.
- 366 4. Jain V, Bos H, Bujold E. Guideline No. 402: Diagnosis and Management of  
367 Placenta Previa. *J Obstet Gynaecol Can.* 2020;42:906-917.e1. doi:  
368 10.1016/j.jogc.2019.07.019.
- 369 5. Gyamfi-Bannerman C. Society for Maternal-Fetal Medicine (SMFM) Consult  
370 Series #44: Management of bleeding in the late preterm period. *Am J Obstet*  
371 *Gynecol.* 2018;218:B2-8. doi: 10.1016/j.ajog.2017.10.019.
- 372 6. Jauniaux E, Silver RM. Rethinking prenatal screening for anomalies of placental  
373 and umbilical cord implantation. *Obstet Gynecol.* 2020;136:1211-1216. doi:  
374 10.1097/AOG.0000000000004175.

- 375 7. Jauniaux E, Grønbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology  
376 of placenta previa accreta: a systematic review and meta-analysis. *BMJ Open*.  
377 2019;9(11):e031193. doi:10.1136/bmjopen-2019-031193.
- 378 8. Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with  
379 cesarean delivery for mother, baby, and subsequent pregnancies: Systematic  
380 review and meta-analysis. *PLoS Med*. 2018;15:e1002494. doi:  
381 10.1371/journal.pmed.1002494.
- 382 9. Jauniaux E, Moffett A, Burton GJ. Placental Implantation Disorders. *Obstet*  
383 *Gynecol Clin North Am*. 2020;47:117-32. doi: 10.1016/j.ogc.2019.10.002.
- 384 10. Petersen SH, Bergh C, Gissler M, Åsvold BO, Romundstad LB, Tiitinen A,  
385 Spangmose AL, et al. Time trends in placenta-mediated pregnancy  
386 complications after assisted reproductive technology in the Nordic countries.  
387 *Am J Obstet Gynecol*. 2020;223:226.e1-226.e19. doi:  
388 10.1016/j.ajog.2020.02.030.
- 389 11. Sentilhes L, Vayssière C, Deneux-Tharaux C, Aya AG, Bayoumeu F, Bonnet  
390 M-P, et al. Postpartum hemorrhage: guidelines for clinical practice from the  
391 French College of Gynaecologists and Obstetricians (CNGOF). *Eur J Obstet*  
392 *Gynecol Reprod Biol*. 2016;198:12-21. doi: 10.1016/j.ejogrb.2015.12.012.
- 393 12. Matsubara S, Ohkuchi A, Kikkawa M, Izumi A, Kuwata T, Usui R, et al. Blood  
394 loss in low-lying placenta: placental edge to cervical internal os distance of less  
395 vs. more than 2 cm. *J Perinat Med*. 2008;36:507-12. doi:  
396 10.1515/JPM.2008.089.
- 397 13. Bronsteen R, Valice R, Lee W, Blackwell S, Balasubramaniam M, Comstock C.  
398 Effect of a low-lying placenta on delivery outcome. *Ultrasound Obstet Gynecol*.  
399 2009;33:204-8. doi: 10.1002/uog.6304.

- 400 14. Vergani P, Ornaghi S, Pozzi I, Beretta P, Russo FM, Follesa I, et al. Placenta  
401 previa: distance to internal os and mode of delivery. *Am J Obstet Gynecol.*  
402 2009;201:266.e1-266.e5. doi: 10.1016/j.ajog.2009.06.009.
- 403 15. Bhide A, Prefumo F, Moore J, Hollis B, Thilaganathan B. Placental edge to  
404 internal os distance in the late third trimester and mode of delivery in placenta  
405 praevia. *BJOG.* 2003;110:860-4. doi: DOI:10.1016/S1470-0328(03)02991-4.
- 406 16. Al Wadi K, Schneider C, Burym C, Reid G, Hunt J, Menticoglou S. Evaluating  
407 the Safety of Labour in Women With a Placental Edge 11 to 20 mm From the  
408 Internal Cervical Os. *J Obstet Gynaecol Can.* 2014;36:674-7. doi:  
409 10.1016/S1701-2163(15)30508-9.
- 410 17. Wortman AC, Twickler DM, McIntire DD, Dashe JS. Bleeding complications in  
411 pregnancies with low-lying placenta. *J Matern Fetal Neonatal Med.*  
412 2016;29:1367-71. doi: 10.3109/14767058.2015.1051023.
- 413 18. Taga A, Sato Y, Sakae C, Satake Y, Emoto I, Maruyama S, et al. Planned  
414 vaginal delivery versus planned cesarean delivery in cases of low-lying  
415 placenta. *J Matern Fetal Neonatal Med.* 2017;30:618-22. doi:  
416 10.1080/14767058.2016.1181168.
- 417 19. Alouini S, Megier P, Fauconnier A, Huchon C, Fievet A, Ramos A, et al.  
418 Diagnosis and management of placenta previa and low placental implantation.  
419 *J Matern Fetal Neonatal Med.* 2020;33:3221-6. doi:  
420 10.1080/14767058.2019.1570118.
- 421 20. Ornaghi S, Vaglio Tessitore I, Vergani P. Pregnancy and delivery outcomes in  
422 women with persistent versus resolved low-lying placenta in the late third  
423 trimester. *J Ultrasound Med.* 2021. doi: 10.1002/jum.15687.

- 424 21. Bienstock JL, Eke AC, Hueppchen NA. Postpartum Hemorrhage. *N Engl J Med.*  
425 2021;384(17):1635-45. doi: 10.1056/NEJMra1513247.
- 426 22. Practice Bulletin No. 183: Postpartum Hemorrhage. *Obstet Gynecol.* oct  
427 2017;130(4):e168-86. doi: 10.1097/AOG.0000000000002351.
- 428 23. Deneux-Tharaux C, Sentilhes L, Maillard F, Closset E, Vardon D, Lepercq J, et  
429 al. Effect of routine controlled cord traction as part of the active management of  
430 the third stage of labour on postpartum haemorrhage: multicentre randomised  
431 controlled trial (TRACOR). *BMJ.* 2013;346:f1541. doi: 10.1136/bmj.f1541.
- 432 24. Sentilhes L, Winer N, Azria E, Sénat M-V, Le Ray C, Vardon D, et al.  
433 Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. *N Engl*  
434 *J Med.* 2018;379:731-42. doi: 10.1056/NEJMoa1800942.
- 435 25. Sentilhes L, Sénat MV, Le Lous M, Winer N, Rozenberg P, Kayem G, et al.  
436 Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. *N*  
437 *Engl J Med.* 2021;384(17):1623-1634. doi:10.1056/NEJMoa2028788
- 438 26. Ornaghi S, Colciago E, Vaglio Tessitore I, Abbamondi A, Antolini L, Locatelli A,  
439 et al. Mode of birth in women with low-lying placenta: protocol for a prospective  
440 multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA  
441 study). *BMJ Open.* 2021;11(12):e052510. doi: 10.1136/bmjopen-2021-052510.
- 442 27. Sentilhes L, Gromez A, Razzouk K, Resch B, Verspyck E, Marpeau L. B-Lynch  
443 suture for massive persistent postpartum hemorrhage following stepwise  
444 uterine devascularization. *Acta Obstet Gynecol Scand.* 2008;87:1020-6. doi:  
445 10.1080/00016340802380750.
- 446 28. Sentilhes L, Gromez A, Clavier E, Resch B, Verspyck E, Marpeau L. Predictors  
447 of Failed Pelvic Arterial Embolization for Severe Postpartum Hemorrhage.  
448 *Obstet Gynecol.* 2009;113:992-9. doi: 10.1097/AOG.0b013e3181a114f7.

- 449 29. Sentilhes L, Trichot C, Resch B, Sergent F, Roman H, Marpeau L, et al. Fertility  
450 and pregnancy outcomes following uterine devascularization for severe  
451 postpartum haemorrhage. *Hum Reprod.* 2008;23:1087-92. doi:  
452 10.1093/humrep/den049.
- 453 30. Ducarme G, Hamel J-F, Bouet P-E, Legendre G, Vandenbroucke L, Sentilhes  
454 L. Maternal and neonatal morbidity after attempted operative vaginal delivery  
455 according to fetal head station. *Obstet Gynecol.* 2015;126:521-9. doi:  
456 10.1097/AOG.0000000000001000.
- 457 31. Sentilhes L, Vayssière C, Beucher G, Deneux-Tharaux C, Deruelle P,  
458 Diemunsch P, et al. Delivery for women with a previous cesarean: guidelines  
459 for clinical practice from the French College of Gynecologists and Obstetricians  
460 (CNGOF). *Eur J Obstet Gynecol Reprod Biol.* 2013;170:25-32. doi:  
461 10.1016/j.ejogrb.2013.05.015.
- 462 32. Rosenbaum PR, Rubin DB. The central role of the propensity score in  
463 observational studies for causal effects. *Biometrika.* 70:41-55.  
464 <https://doi.org/10.1093/biomet/70.1.41>
- 465 33. Austin PC. An Introduction to Propensity Score Methods for Reducing the  
466 Effects of Confounding in Observational Studies. *Multivar Behav Res.*  
467 2011;46:399-424. doi: 10.1080/00273171.2011.568786.
- 468 34. Rubin DB, Schenker N. Multiple imputation in health-care databases: An  
469 overview and some applications. *Stat Med.* avr 1991;10(4):585-98. doi:  
470 10.1002/sim.4780100410.
- 471 35. Jansen C, Mooij Y, Blomaard C, Derks J, Leeuwen E, Limpens J, et al. Vaginal  
472 delivery in women with a low-lying placenta: a systematic review and meta-  
473 analysis. *BJOG.* 2019;126:1118-26. doi: 10.1111/1471-0528.15622.

- 474 36. Ghourab S. Third-trimester transvaginal ultrasonography in placenta previa:  
475 does the shape of the lower placental edge predict clinical outcome? *Ultrasound*  
476 *Obstet Gynecol* 2001;18:103–8. doi: 10.1046/j.1469-0705.2001.00420.x.
- 477 37. Saitoh M, Ishihara K, Sekiya T, Araki T. Anticipation of uterine bleeding in  
478 placenta previa based on vaginal sonographic evaluation. *Gynecol Obstet*  
479 *Invest* 2002;54:37–42. doi: 10.1159/000064695.

480 **Tables**

481 **Table 1.** Maternal Characteristics of the Study Population by Planned Mode of Delivery  
 482 (n=171).

Maternal Characteristics	Trial of Labor group n = 70	Elective Cesarean Delivery group n = 101	<i>P</i>
Maternal age (y) median [IQR]	31 [28-35]	32 [29-35]	.7
> 30	39 (55.7)	58 (57.4)	.8
BMI before pregnancy (kg/m <sup>2</sup> ) median [IQR]	22 [19-26]	23 [20-25]	.5
<18.5	12 (18.2)	10 (10.9)	.4
[18.5-25[	37 (56.1)	60 (65.2)	
[25-30[	11 (16.7)	17 (18.5)	
≥ 30	6 (9.1)	5 (5.4)	
Tobacco use during pregnancy	11 (15.7)	23 (22.8)	.4
Drug addiction	2 (2.9)	0	.2
Preexisting hypertensive disorder	1 (1.3)	2 (2.0)	.8
Nulliparity	20 (28.6)	30 (29.7)	.9
Multiple gestation	1 (1.4)	5 (5.0)	.2
Previous uterine curettage	10 (14.3)	30 (29.7)	.05
Previous myomectomy	0	3 (3.0)	.1
Previous cesarean delivery	3 (4.3)	17 (16.8)	.01
Previous postpartum hemorrhage	5 (7.1)	5 (5.0)	.5
Previous placenta previa	2 (2.9)	2 (2.0)	.7
Previous preterm birth	3 (4.3)	7 (6.9)	.5
Medically assisted reproduction	6 (8.6)	13 (12.9)	.4
Antepartum hemorrhage *	54 (77.1)	52 (51.5)	<.01
First episode <29 weeks †	7 (13.0)	11 (21.2)	.3
Recurrent episodes ≥ 3	7 (9.4)	25 (25.0)	.01
Antepartum hospitalization	54 (77.1)	67 (66.3)	.1
for antepartum hemorrhage †	51 (82.3)	48 (60.7)	<.01
Interval between delivery and last ultrasound scan (d) median [IQR]	4 [0-16]	10.5 [3-17]	<.01
Anterior placental location	17 (24.6)	28 (28.0)	.6
Internal os distance median [IQR]	13.5 [9-17]	9 [0-13]	<.01
0-10 mm ‡	27 (41.5)	67 (68.4)	<.01



11-20 mm ‡

38 (58.5)

31 (31.6)

< .01

483 *BMI: body mass index; IQR: interquartile range.*

484 \* Antepartum hemorrhage was defined by a blood loss during the pregnancy not requiring an  
485 immediate birth.<sup>4,5</sup> Gestational age of the first episode of antepartum hemorrhage < 29 weeks  
486 gestation and number of recurrent episodes of antepartum hemorrhage (≥3) are both  
487 associated with increased risk of emergency cesarean delivery.<sup>4</sup>

488 Continuous data are expressed as medians [IQR] when specified; discrete data are expressed  
489 as n (%). Kruskal-Wallis,  $\chi^2$ , and Fisher's exact tests were used as appropriate. A *P* value of  
490 .05 was considered significant.

491 † Missing data: > 10%.

492 ‡ There were 5 and 3 missing data for the planned trial of labor and cesarean groups,  
493 respectively, because in these cases, the cervix-to-placenta distance was reported as <20 mm  
494 but not otherwise specified.

495

496 **Table 2.** Maternal and Neonatal Outcomes by Planned Mode of Delivery (n=171).

497

Outcomes	Trial of Labor group n = 70	Elective Cesarean Delivery group n = 101	P
<b>Maternal outcomes</b>			
Primary outcome			
Severe PPH ≥ 1,000 mL	16 (22.9)	23 (23.0)	.9
Mode of delivery			
Cesarean delivery	43 (61.4)	101 (100.0)	<.01
Emergency cesarean before labor for hemorrhage*,†	15/68 (22.1)	21/31 (67.7)	<.01
Emergency cesarean during labor for hemorrhage*,†	10/68 (14.7)	1/31 (3.2)	<.01
General endotracheal anesthesia	13/43 (30.2)	26/101 (25.7)	.6
Vaginal delivery	27 (38.6)	0	< .01
Operative vaginal delivery	2 (2.9)	0	0.2
Estimated blood loss (mL) ‡ median [IQR]	500 [300-950]	675 [350-1000]	.8
Postpartum hemorrhage ≥ 500 mL	32 (45.7)	53 (53.0)	.4
Use of additional uterotonic agent	5 (7.1)	7 (6.9)	.9
Blood transfusion			
Red blood cells	6 (8.6)	7 (6.9)	.7
> 5 units of packed red blood cells transfused	0	1 (1.0)	.4
Fresh frozen plasma	2 (2.9)	2 (2.0)	.7
Fibrinogen	1 (1.4)	0	.2
Pelvic arterial embolization	1 (1.4)	0	.2
Second-line surgical therapies §	1 (1.4)	1 (1.0)	.7
Admission to intensive care	0	1 (1.0)	.4
Length of hospital stay (days) median [IQR]	5 [4-6.5]	6 [5-6]	.2
Postpartum anemia (< 10 g/dL) during hospital stay	48 (69.6)	68 (67.3)	.7
Thromboembolic events	0	0	
Postpartum fever	0	1 (1.0)	
Sepsis	0	1 (1.0)	
Maternal death	0	0	
Severe maternal morbidity ¶	2 (2.9)	2 (2.0)	.7
<b>Neonatal outcomes</b>			
Gestational age at delivery median [IQR]	38 [36-40]	37 [37-38]	.05

between 35 <sup>0</sup> and 36 <sup>6</sup> weeks	20 (28.6)	20 (19.8)	.2
between 37 <sup>0</sup> and 39 <sup>6</sup> weeks	33 (47.1)	79 (78.2)	<.01
≥ 40 <sup>0</sup> weeks	17 (24.3)	2 (2.0)	<.01
Birthweight (g) median [IQR]	3050 [2665-3460]	2985 [2780-3275]	.5
Umbilical cord arterial pH < 7.10	1 (1.7)	1 (1.0)	.8
Apgar score < 7 at 5 minutes	5 (7.3)	3 (3.0)	.2
Respiratory distress syndrome	9 (12.9)	5 (5.0)	.06
Need for resuscitation or intubation	5 (7.1)	8 (7.9)	.8
Transfer to neonatal intensive care unit	14 (20.0)	11 (10.9)	.1
Neonatal death	1 (1.4)	0	.2
Severe neonatal morbidity #	9 (12.9)	10 (9.9)	.5

498 *IQR: interquartile range*

499 Continuous data are expressed as medians [IQR] when specified; discrete data are expressed as n (%).  
500 Kruskal-Wallis,  $\chi^2$ , and Fisher's exact tests were used as appropriate. A *P* value of .05 was considered  
501 significant.

502

503 \* Missing data: > 10%.

504 † Other indications for cesarean deliveries were abnormal fetal heart rate without hemorrhage during  
505 labor and protracted labor.

506 ‡ There were 15 and 21 missing data for the planned trial of labor group and 21 for elective cesarean  
507 groups.

508 § Second-line surgical therapies: uterine compression sutures, vessel ligation, and peripartum  
509 hysterectomy for management of massive primary postpartum hemorrhage after uterine massage and  
510 uterotonic agents failed to stop bleeding.

511 || Postpartum fever was defined by an isolated postpartum fever higher than 38.5°C, and sepsis by a  
512 positive blood culture.

513 ¶ Severe maternal morbidity, defined by any one of the following: uterine artery embolization or  
514 emergency surgery to control PPH (i.e., vessel ligation and/or uterine compression sutures and/or  
515 peripartum hysterectomy), transfusion of more than 5 units of packed red blood cells, transfer to  
516 intensive care unit, thromboembolic events, or death.

517 # Severe neonatal morbidity, defined by any one of the following: 5-minute Apgar score less than 7,  
518 umbilical artery pH less than 7.10 (umbilical artery blood gas values were routinely measured), need for  
519 resuscitation or intubation, and neonatal death.

520 **Table 3.** Maternal and Neonatal Outcomes by Planned Mode of Delivery for Women  
 521 with Cervix-to-Placenta distances of 1-10 mm and 11-20 mm (n=163)\*.

Outcomes	Internal Os Distance: 1-10 mm			Internal Os Distance: 11-20 mm		
	Trial of Labor n = 27	Elective Cesarean Delivery n = 67	P	Trial of Labor n = 38	Elective Cesarean Delivery n = 31	P
<b>Maternal outcomes</b>						
Severe postpartum hemorrhage ≥1,000 mL	5 (18.5)	19 (28.8)	.3	10 (26.3)	4 (12.9)	.2
Mode of delivery						
Cesarean delivery	22 (81.5)	67 (100)	<.01	19 (50.0)	31 (100)	<.01
Emergency cesarean delivery before labor for hemorrhage †,‡	6/26 (23.1)	15/21 (71.4)	<.01	9/37 (24.3)	5/9 (55.6)	.1
Emergency cesarean delivery during labor for hemorrhage †,‡	7/26 (26.9)	1/21 (4.8)	.02	1/37 (2.7)	0	.5
General endotracheal anesthesia	4/22 (18.2)	21/67 (31.3)	.2	7/19 (36.8)	6/31 (19.4)	.1
Vaginal delivery	5 (18.5)	0	<.01	19 (50.0)	0	<.01
Instrumental delivery	1 (3.7)	0	.1	0	0	-
Estimated blood loss (mL) median [IQR]	500 [300-650]	800 [400-1100]	.4	650 [300-1000]	500 [300-800]	.9
Postpartum hemorrhage ≥ 500 mL	13 (48.2)	38 (57.6)	.4	18 (47.4)	14 (45.2)	.8
Use of additional uterotonic agent	2 (7.4)	7 (10.5)	.7	3 (7.9)	0	.1
Blood transfusion						
Red blood cells	2 (7.4)	7 (10.5)	.7	4 (10.5)	0	.06
Fresh frozen plasma	0	2 (3.0)	.4	2 (5.4)	0	.2
Fibrinogen	0	0	-	0	0	-
Pelvic arterial embolization	1 (3.7)	0	.1	0	0	-
Second-line surgical therapies §	0	1 (1.5)	.5	1 (2.6)	0	.4
Admission to intensive care unit	0	1 (1.5)	.5	0	0	-
Length of hospital stay (days) median [IQR]	6 [4-7]	6 [5-7]	.2	5 [4-6.5]	5 [5-6]	.2
Postpartum anemia (< 10 g/dL) during hospital stay	19 (70.4)	44 (65.7)	.7	27 (73.0)	21 (67.7)	.6
Thromboembolic events	0	0	-	0	0	-
Postpartum fever	0	1 (1.5)	.5	0	0	-
Sepsis	0	1 (1.5)	.5	0	0	-
Maternal death	0	0	-	0	0	-
Severe maternal morbidity ¶	1 (3.7)	2 (3.0)	.9	1 (2.6)	0	.4
<b>Neonatal outcomes</b>						

Gestational age at delivery, median [IQR]	37 [36-40]	37 [37-38]	.05	38 [37-39]	38 [37-39]	.06
between 35 <sup>0</sup> and 36 <sup>6</sup> weeks	11 (40.7)	15 (22.4)	.07	8 (21.1)	4 (12.9)	.4
between 37 <sup>0</sup> and 39 <sup>6</sup> weeks	10 (34.0)	51 (76.1)	<.01	22 (57.9)	26 (83.9)	.02
≥ 40 <sup>0</sup> weeks	6 (22.2)	1 (1.5)	<.01	8 (21.1)	1 (3.2)	.03
Birthweight (g) median [IQR]	2810	2950	.5	3150	3030	.4
	[2620-3430]	[2690-3330]		[2670-3520]	[2870-3230]	
Umbilical cord arterial pH < 7.10	0	0	-	1 (3.1)	1 (3.5)	.9
Apgar score < 7 at 5 minutes	3 (11.5)	2 (3.0)	.1	2 (5.3)	1 (3.2)	.7
Respiratory distress syndrome	4 (14.8)	3 (4.5)	.08	5 (13.2)	2 (6.5)	.4
Transfer to neonatal intensive care unit	3 (11.1)	7 (10.5)	.9	2 (5.3)	1 (3.2)	.7
Neonatal death	1 (3.7)	0	.1	0	0	-
Severe neonatal morbidity #	5 (18.5)	7 (10.5)	.3	4 (10.5)	3 (9.7)	.9

522 *IQR: interquartile range.*

523 Continuous data are expressed as medians [IQR] when specified; discrete data are expressed as n (%). Kruskal-  
524 Wallis,  $\chi^2$ , and Fisher's exact tests were used as appropriate. A *P* value of .05 was considered significant.

525 \* There were 5 and 3 missing data for the planned trial of labor and elective cesarean groups,  
526 respectively, because in these cases, the internal os distance was reported as <20 mm but not otherwise  
527 specified.

528 † Missing data: > 10%.


529 ‡ Other indications for cesarean deliveries were abnormal fetal heart rate without hemorrhage during  
530 labor and protracted labor.

531 § Second-line surgical therapies: uterine compression sutures, vessels ligation, and peripartum  
532 hysterectomy for management of massive primary postpartum hemorrhage after uterine massage and  
533 uterotonic agents failed to stop bleeding.

534 || Postpartum fever was defined by an isolated postpartum fever higher than 38.5°C, and sepsis by a  
535 positive blood culture.

536 ¶ Severe maternal morbidity, defined by any one of the following: uterine artery embolization or  
537 emergency surgery to control PPH (i.e., vessel ligation and/or uterine compression sutures and/or  
538 peripartum hysterectomy), transfusion of more than 5 units of packed red blood cells, transfer to  
539 intensive care unit, thromboembolic events, and death.

540 # Severe neonatal morbidity, defined by any one of the following: 5-minute Apgar score < 7, umbilical  
541 artery pH < 7.10 (umbilical artery blood gas values were routinely measured), need for resuscitation or  
542 intubation, and neonatal death.



544


545 **Figure 1.** Study flow chart.

546 \* low-lying placenta was defined as a distance between the placental edge and the

547 cervical os of less than 20 mm at the last transvaginal ultrasound scan before delivery;

548 placenta previa was defined as the placenta lying directly over the cervical os.<sup>1</sup>

549 *PAS, placenta accreta spectrum.*



550

551 **Figure 2.** Risk of severe postpartum hemorrhage in the trial-of-labor group (reference:  
 552 elective cesarean delivery) for the main analysis, including all deliveries at and after  
 553 35 weeks gestation (n=171).

554 *CI, confidence interval; OR, odds ratio.*

555

556 **Supplemental files**

557 **Appendix A. Univariate and multivariate analysis of severe postpartum**  
 558 **hemorrhage according to the planned mode of delivery.**

559

	Severe Postpartum Hemorrhage $\geq$ 1000 mL		
	Crude OR (95% CI)	Adj. OR (95% CI)	P *
Planned mode of delivery			
Elective cesarean delivery	Ref	Ref	
Trial of labor	0.99 (0.48-2.05)	1.42 (0.62-3.24)	.5
Maternal age >30 (years)	1.46 (0.70-3.06)	1.68 (0.71-3.94)	.2
BMI before pregnancy $\geq$ 30 (kg/m <sup>2</sup> )	2.04 (0.56-7.39)	2.04 (0.53-7.23)	.3
Nulliparity	0.55 (0.23-1.29)	0.70 (0.27-1.88)	.5
Previous cesarean delivery	3.27 (1.24-8.61)	2.28 (0.69-4.87)	.2
Tobacco use during pregnancy	1.52 (0.66-3.49)	-	-
First episode of antepartum hemorrhage <29 weeks	0.43 (0.09-2.00)	-	-
Recurrent episodes of antepartum hemorrhage ( $\geq$ 3)	1.14 (0.56-2.32)	-	-
Anterior placental location	0.56 (0.26-1.22)	-	-
Internal os distance, 0-10 mm	1.37 (0.65-2.89)	1.51 (0.66-3.47)	.3

560 *OR, odds ratio; CI, confidence interval; BMI, body mass index.*

561 \* Adjusted logistic regression analyses. Adjustment for maternal age, BMI, nulliparity, previous  
 562 cesarean delivery, and cervix-to-placenta distance. The number of adjustment variables  
 563 included is limited due to the low number of events (n=39).

564

565

566

567

568

569

570

571


572

573

574



575 **Appendix B. Absolute standardized differences**



576

577 Absolute standardized differences between women with planned trial of labor or elective  
 578 cesarean delivery, for the variables included in the propensity score, before (total population)  
 579 and after propensity score weighting (propensity score-weighted population).

580 *Absolute standardized difference is a measure of effect size between two groups that is*  
 581 *independent of sample size. It is the absolute value of the mean difference divided by the*  
 582 *pooled standard deviation.*

583

